Pakistan’s progress toward its Sustainable Development Goals (SDGs) is severely hindered by persistently high smoking rates and the resulting health crisis. With over 31 million smokers and more than 160,000 smoking-related deaths annually, the country’s efforts to reduce preventable diseases and economic burdens remain ineffective. Despite strict tobacco control measures, smoking prevalence remains alarmingly high, putting immense pressure on the healthcare system and slowing down Pakistan’s SDG progress. Without a shift in strategy, Pakistan risks falling even further behind in achieving its commitments.
A recent global development offers a potential solution – the U.S. Food and Drug Administration (FDA) has authorized ZYN nicotine pouches as a better alternative to smoking. This landmark decision highlights the crucial role of harm reduction in curbing smoking-related illnesses and minimizing health risks. While the U.S. is advancing with a science-backed, regulated approach to smoke-free alternatives, Pakistan has yet to implement a structured strategy. This delay not only deprives smokers of viable alternatives but also hinders the country’s ability to address smoking-related health and economic challenges.
ZYN nicotine pouches are already available in Pakistan but remain in a regulatory gray area. Unlike in the U.S., where the FDA enforces strict quality control, safety measures, and responsible marketing, Pakistan lacks a formal framework to assess and regulate these products. This policy vacuum is a missed opportunity for a nation grappling with one of the highest smoking rates in the world. Without regulation, consumers are left exposed to unverified products while being denied scientifically-backed alternatives that could significantly reduce health risks.
Hence, without embracing harm reduction, Pakistan’s SDG progress will remain stagnant, leaving millions vulnerable to the devastating consequences of smoking.
